Clinton/Reid Bill Would Boost Cancer Tracking at CDC

Publication
Article
OncologyONCOLOGY Vol 16 No 8
Volume 16
Issue 8

Now that President Bush has appointed Julie Gerberding to head the Centers for Disease Control and Prevention (CDC), groups like the Trust for America’s Health are urging her to make cancer tracking a priority.

Now that President Bush has appointed Julie Gerberding to head the Centersfor Disease Control and Prevention (CDC), groups like the Trust for America’sHealth are urging her to make cancer tracking a priority. 

A new bill—the Nationwide Health Tracking Act—introduced by Sen. HillaryClinton (D-NY) and Sen. Harry Reid (D-Nev) would authorize $227.5 million a yearfor expansion of a pilot CDC chronic disease tracking program. The Clinton/Reidbill, which has a counterpart in the House, grew out of hearings held in Fallon,Nev, and Long Island, NY, that focused on possible environmental links to cancerin those communities. 

Congress gave the CDC $17.5 million in fiscal 2002 to help get itsenvironmental health-tracking program off the ground. But at that funding level,the program’s reach is limited. Shelley Hearne, executive director of theTrust, points out that Congress just gave the CDC an extra $1 billion forbioterrorism. "But this funding and the CDC’s guidelines on how to spendit do not help the nation prepare for the number 1 killer of Americans today—chronicdiseases like cancer, asthma, and Parkinson’s disease," she states.

Articles in this issue
Irinotecan and Other Agents in New Combinations and Other Tumor Types
New Edition of Cancer Care’s Helping Hand Available
Handbook of Gynecologic Oncology
First Study to Show Chemotherapy Extends Survival of Advanced Prostate Cancer Patients
Clinton/Reid Bill Would Boost Cancer Tracking at CDC
Novartis Seeks to Market Gleevec for First-Line Use in Chronic Myeloid Leukemia
Docetaxel Improves Survival in Node-Positive Early-Stage Breast Cancer Patients
Docetaxel/Platinum Combination Provides Quality-of-Life Advantage Over Vinorelbine/Cisplatin in Advanced Lung Cancer
House Restores Some Medicare Physician Pay Cuts
Medicare Proposes Calendar 2003 Pay Rate
Mathematical Modeling for Breast Cancer Risk Assessment
What Is the Optimal Therapy for Childhood AML?
Current Management of Depression in Cancer Patients
Current Clinical Trials of the Cancer Trials Support Unit (CTSU), an NCI Pilot Program
Mathematical Modeling for Breast Cancer Risk Assessment
Recent Videos
2 KOLs are featured in this series.
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
2 experts are featured in this series.
2 experts are featured in this series.
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
A new partnership agreement involving AI use may help spread radiotherapeutic standards from academic centers to more patients in community-based practices.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
Related Content
Allireza Alloo, MD

An Oncodermatologist’s Perspective on Dermatological Toxicities in Breast Cancer

Tim Cortese
October 27th 2025
Article

Onco-dermatology enhances patient care and quality of life by addressing skin toxicities in breast cancer treatments through expert management and collaboration.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

The anti–CTLA-4 antibody combination achieved an ORR of 34.8%, with 8 partial responses, in patients with pretreated microsatellite stable mCRC.

Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer

Tim Cortese
October 27th 2025
Article

The anti–CTLA-4 antibody combination achieved an ORR of 34.8%, with 8 partial responses, in patients with pretreated microsatellite stable mCRC.

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

Anne Chiang, MD
October 20th 2025
Podcast

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Data from the REZILIENT2 trial show meaningful intracranial activity in patients with NSCLC harboring EGFR exon 20 insertions or other uncommon mutations.

Zipalertinib Yields Early Activity in EGFR+ NSCLC CNS Metastasis Population

Caroline Seymour
October 26th 2025
Article

Data from the REZILIENT2 trial show meaningful intracranial activity in patients with NSCLC harboring EGFR exon 20 insertions or other uncommon mutations.

Grade 3 or 4 AEs were experienced by 42.9% of patients who received cisplatin plus radiation compared with 15.3% of patients who received radiation alone.

CRT Does Not Improve RFS/OS, Confers High-Grade Toxicity in Cervical Cancer

Tim Cortese
October 26th 2025
Article

Grade 3 or 4 AEs were experienced by 42.9% of patients who received cisplatin plus radiation compared with 15.3% of patients who received radiation alone.